A Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia
Research article published in Cureus (2022)
Abstract
This report discusses a case of a 37-year-old female who developed vaccine-induced thrombotic thrombocytopenia (VITT) after receiving the Johnson and Johnson COVID-19 vaccination. The patient first presented to the ED with complaints of a worsening headache. Labs were significant for thrombocytopenia with a platelet count of 22,000, and the patient was admitted to the inpatient unit for monitoring. The day after admission, the patient was found to have a right common femoral artery embolus, left distal popliteal trifurcation embolism, a small pulmonary embolism in the right lower lobe, and a mural thrombus of the infrarenal abdominal aorta. Following these findings, the patient underwent emergent thrombectomy of the common and superficial femoral arteries. Over the hospital course of six days, the patient received steroids and IV immunoglobulin (IVIG), which led to the resolution of the thrombocytopenia. The patient was given argatroban followed by apixaban for anticoagulation. She was instructed to follow up with hematology within one to two weeks post-discharge for monitoring of anticoagulation and thrombus surveillance. This case report outlines the clinical course, diagnosis, and treatment of a case of VITT, which will assist physicians in early recognition and adequate treatment of this condition as the COVID-19 pandemic continues.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to anticoagulation, leech therapy, and microsurgical flap management. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Este informe de caso detalla la trombocitopenia trombótica inducida por vacuna (VITT) en una mujer de 37 años después de la vacunación contra el COVID-19 de Johnson & Johnson, que presenta trombocitopenia severa y múltiples trombosis arteriales y venosas manejadas con trombectomía, corticosteroides, inmunoglobulina intravenosa (IVIG) y los anticoagulantes no heparínicos argatroban y luego apixaban. Su relevancia para la hirudoterapia es indirecta: la VITT, al igual que la HIT, es un síndrome protrombótico impulsado por anticuerpos anti-PF4 en el que se evita generalmente la heparin, lo que refuerza la justificación de los inhibidores directos de la trombina independientes de la heparina, una clase de fármacos a la que pertenece la hirudin derivada de la lombriz. Nota: este es un caso único procedente de la pandemia inicial sobre una complicación vacunal; no implica terapia con lombriz medicinal y no proporciona evidencia directa a favor ni en contra de la hirudoterapia.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026